Download PDF
Rofo 2003; 175(6): 752-765
DOI: 10.1055/s-2003-39935
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Superparamagnetische Eisenoxidpartikel: Aktueller Stand und zukünftige Entwicklungen

Superparamagnetic Iron Oxide Particles: Current State and Future DevelopmentM.  Taupitz1 , S.  Schmitz2 , B.  Hamm1
  • 1Institut für Radiologie, Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin
  • 2Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin
Prof. Dr. Dr. h.c. Karl-Jürgen Wolf zum 60. Geburtstag gewidmet
Further Information

Publication History

Publication Date:
17 June 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Für Superparamagnetische Eisenoxidpartikel (SPIO) ist in den letzten 15 Jahren ein weites Anwendungsspektrum als Kontrastmittel für die MRT aufgezeigt worden. SPIO können mit verschiedenen Partikelgrößen und Oberflächenbeschichtungen hergestellt werden. SPIO mit größeren Partikeldurchmessern (50 - 150 nm) bewirken überwiegend eine Signalminderung bzw. T2-Verkürzung, werden als Kontrastmittel in der MRT von Leber und Milz eingesetzt und führen zu einer hohen Genauigkeit vor allem im Nachweis von Lebermetastasen (zugelassene Substanzen: AMI-25 (Endorem bzw. Ferridex), SHU-555A (Resovist)). Kleinere Partikel (ca. 20 nm Durchmesser) zeigen eine andere Organverteilung und haben das Potenzial, die nicht-invasive Lymphknotendiagnostik zu verbessern oder vulnerable atherosklerotische Plaques zu charakterisieren (in der klinischen Prüfung: AMI-227 [Sinerem bzw. Combidex]). Partikel mit optimierter T1-Relaxivität und verlängerter intravasaler Zirkulationszeit sind als Blutpool-Kontrastmittel für die MR-Angiographie einsetzbar. Als Indikationen werden derzeit die MR-Angiographie des Körperstamms, peripherer Arterien und der Koronararterien geprüft (z. B. SHU 555 C (Supravist), VSOP-C184). Weitere derzeit in der Prüfung befindliche Indikationen kleiner SPIO sind die MRT des Knochenmarks sowie die Bestimmung von Parametern der Perfusion von Tumoren oder z. B. des Myokards. Eine entsprechende Modifikation der Partikelhülle ermöglicht Ansätze der sogenannten Molekularen Bildgebung, z. B. Rezeptor-gerichtete Bildgebung, Markierung von Zellen zum in-vivo Monitoring der Zellmigration, z. B. von Stammzellen, Markierung von Genkonstrukten zur Lokalisationskontrolle in der Gentherapie. In der Tumortherapie können SPIO als Vermittler für die Hyperthermie eingesetzt werden. SPIO stellen ein wirkungsvolles MR-Kontrastmittel mit vielseitigen Einsatzmöglichkeiten in der Bildgebenden Diagnostik bis hin zur Molekularen Medizin dar.

Abstract

A wide range of applications for superparamagnetic iron oxide (SPIO) particles as contrast media for MRI has emerged over the last 15 years. SPIO particles can be manufactured with different particle sizes and surface coatings. Large SPIO particles (50 - 150 nm) predominantly produce a signal decrease or T2-shortening and are used as contrast media for MRI of the liver and spleen. They have a high accuracy, especially in detecting liver metastases (approved for clinical use: AMI-25 (Endorem or Ferridex), SHU-555A (Resovist)). Smaller particles (about 20 nm in diameter) show a different organ distribution and have a potential for improving noninvasive lymph node assessment or characterizing vulnerable atherosclerotic plaques (in clinical trials: AMI-227 [Sinerem or Combidex]). Particles with an optimized T1-relaxivity and prolonged intravascular circulation time can be used as blood pool contrast media for MR angiography. The currently investigated indications are MR angiography of the trunk, peripheral vessels, and coronary arteries (e.g., SHU-555 C (Supravist), VSOP-C 184). Other applications of small SPIO particles include MRI of the bone marrow and the determination of perfusion parameters in tumors or other tissues like the myocardium. SPIO particles with a modified coat can be used in so-called molecular imaging, such as receptor-directed imaging, cell labeling for in-vivo monitoring of cell migration, e.g., stem cell labeling, and labeling of gene constructs for localization in genetic therapy. In tumor therapy SPIO particles can serve as mediators for hyperthermia. SPIO is a powerful MR contrast medium with manifold applications ranging from diagnostic imaging to molecular medicine.

Key words

Magnetic resonance imaging - MRI - contrast medium - iron oxide particles - superparamagnetism

Literatur

  • 1 Kobozev N I, Evdokimov V B, Zubovich I A, Mal'tsev A N. Magnetochemistry of active centers. I. Magnetic and catalytic properties of dilute layers.  Zhur Fiz Khim. 1952;  26 1349-1373
    PubMedGoogle Scholar
  • 2 Bean C P, Jacobs I S. Magnetic granulometry and superparamagnetism.  J Appl Phys. 1956;  27 1448-1452
    CrossrefPubMedGoogle Scholar
  • 3 Kronick P, Gilpin R W. Use of superparamagnetic particles for isolation of cells.  J Biochem Biophys Methods. 1986;  12 73-80
    CrossrefPubMedGoogle Scholar
  • 4 Renshaw P F, Owen C S, Evans A E, Leigh J S. Immunospecific NMR contrast agents.  Magn Reson Imaging. 1986;  4 351-357
    PubMedGoogle Scholar
  • 5 Hemmingsson A, Carlsten J, Ericsson A, Klaveness J, Sperber G O, Thuomas K A. Relaxation enhancement of the dog liver and spleen by biodegradable superparamagnetic particles in proton magnetic resonance imaging.  Acta Radiologica. 1987;  28 703-705
    PubMedGoogle Scholar
  • 6 Saini S, Stark D D, Hahn P F, Wittenberg J, Brady T J, Ferrucci J T. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system.  Radiology. 1987;  162 211-216
    PubMedGoogle Scholar
  • 7 Wang Y X, Hussain S M, Krestin G P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging.  Eur Radiol. 2001;  11 2319-2331
    CrossrefPubMedGoogle Scholar
  • 8 Lawaczeck R, Bauer H, Frenzel T, Hasegawa M, Ito Y, Kito K, Miwa N, Tsutsui H, Vogler H, Weinmann H J. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U 555 A.  Acta Radiologica. 1997;  38 584-597
    PubMedGoogle Scholar
  • 9 Widder D J, Greif W L, Widder K J, Edelman R R, Brady T J. Magnetite albumin microspheres: a new MR contrast material.  Am J Roentgenol. 1987;  148 399-404
    PubMedGoogle Scholar
  • 10 Kreft B P, Tanimoto A, Leffler S, Finn J P, Oksendal A N, Stark D D. Contrast-enhanced MR imaging of diffuse and focal splenic disease with use of magnetic starch microspheres.  J Magn Reson Imaging. 1994;  4 373-379
    PubMedGoogle Scholar
  • 11 Saeed M, Wendland M F, Engelbrecht M, Sakuma H, Higgins C B. Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities.  Eur Radiol. 1998;  8 1047-1053
    CrossrefPubMedGoogle Scholar
  • 12 Paeuser S, Reszka R, Wagner S, Wolf K-J, Buhr H-J, Berger G. Liposome-encapsulated superparamagnetic iron oxide particles as markers in an MRI-guided search for tumor-specific drug carriers.  Anti-Cancer Drug Design. 1997;  12 125-135
    PubMedGoogle Scholar
  • 13 Taupitz M, Schnorr J, Abramjuk C, Wagner S, Pilgrimm H, Hunigen H, Hamm B. New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits.  J Magn Reson Imaging. 2000;  12 905-911
    CrossrefPubMedGoogle Scholar
  • 14 Weissleder R, Stark D D, Engelstad B L, Bacon B R, Campton C C, White D L, Jacobs P, Lewis J. Superparamagnetic iron oxide: pharmacokinetics and toxicity.  Am J Roentgenol. 1989;  152 167-173
    PubMedGoogle Scholar
  • 15 Knollmann F D, Bock J C, Rautenberg K, Beier J, Ebert W, Felix R. Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography: preliminary results of an animal study original investigation.  Invest Radiol. 1998;  33 637-643
    CrossrefPubMedGoogle Scholar
  • 16 Bremer C, Allkemper T, Baermig J, Reimer P. RES-specific iamging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography.  J Magn Reson Imaging. 1999;  10 461-467
    CrossrefPubMedGoogle Scholar
  • 17 Oswald P, Clement O, Chambon C, Schouman-Claeys E, Frija G. Liver positive enhancement after injection of superparamagnetic nanoparticles: respective role of circulating and uptaken particles.  Magn Reon Imaging. 1997;  15 1025-1031
    PubMedGoogle Scholar
  • 18 Hamm B, Reichel M, Vogl T, Taupitz M, Wolf K J. Superparamagnetische Eisenpartikel. Klinische Ergebnisse in der MR-Diagnostik von Lebermetastasen.  Fortschr Röntgenstr. 1994;  160 52-58
    PubMedGoogle Scholar
  • 19 Kehagias D T, Gouliamos A D, Smyrniotis V, Vlahos L J. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A).  J Magn Reson Imaging. 2001;  14 595-601
    CrossrefPubMedGoogle Scholar
  • 20 Müller R D, Vogel K, Neumann K, Hirche H, Barkhausen J, Stoblen F, Henrich H, Langer R. SPIO-MR imaging versus double-phase spiral CT in detecting malignant lesions of the liver.  Acta Radiologica. 1999;  40 628-635
    PubMedGoogle Scholar
  • 21 Ba-Ssalamah A, Heinz-Peer G, Schima W, Schibany N, Schick S, Prokesch R W, Kaider A, Teleky B, Wrba F, Lechner G. Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP.  J Magn Reson Imaging. 2000;  11 665-672
    CrossrefPubMedGoogle Scholar
  • 22 Vogl T J, Hammerstingl R, Pegios W, Hamm B, Eibl-Eibesfeldt A, Woessmer B, Lissner J, Felix R. Wertigkeit des leberspezifischen superparamagnetischen Kontrastmittels AMI-25 für die Detektion und Differentialdiagnose lebereigener Tumoren versus Metastasen.  Fortschr Röntgenstr. 1994;  160 319-328
    PubMedGoogle Scholar
  • 23 Grandin C, Van Beers B E, Robert A, Gigot J F, Geubel A, Pringot J. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration.  J Comput Assist Tomogr. 1995;  19 412-418
    PubMedGoogle Scholar
  • 24 Beets-Tan R G, Van Engelshoven J M, Greve J W. Hepatic adenoma and focal nodular hyperplasia: MR findings with superparamagnetic iron oxide-enhanced MRI.  Clin Imag. 1998;  22 211-215
    CrossrefPubMedGoogle Scholar
  • 25 Bartolotta T V, Midiri M, Galia M, Carcione A, De Maria M, Lagalla R. Benign hepatic tumors: MRI features before and after administration of superparamagnetic contrast media.  Radiologia Medica. 2001;  101 219-229
    PubMedGoogle Scholar
  • 26 Saini S, Edelman R R, Sharma P, Li W, Mayo-Smith W, Slater G J, Eisenberg P J, Hahn P F. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).  Am J Roentgenol. 1995;  164 1147-1152
    PubMedGoogle Scholar
  • 27 Müller M, Reimer P, Wiedermann D, Allkemper T, Marx C, Tombach B, Rummeny E J, Shamsi K, Balzer T, Peters P E. T1-gewichtete dynamische MRT mit neuen superparamagnetischen Eisenoxidpartikeln (Resovist): Ergebnisse einer Studie am Phantom sowie an 25 Patienten.  Fortschr Röntgenstr. 1998;  168 228-236
    PubMedGoogle Scholar
  • 28 Saini S, Sharma R, Baron R L, Turner D A, Ros P R, Hahn P F, Small W C, Delange E E, Stillman A E, Edelman R R, Runge V M, Outwater E K. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging.  Clin Radiol. 2000;  55 690-695
    CrossrefPubMedGoogle Scholar
  • 29 Clement O, Schouman-Claeys E, Frija G. Ferrite particles (AMI25): Influence of cirrhosis and chemotherapy on magnetic resonance imaging of metastasis.  Invest Radiol. 1990;  25 S61-S62
    PubMedGoogle Scholar
  • 30 Kato N, Ihara S, Tsujimoto T, Miyazawa T. Effect of resovist on rats with different severities of liver cirrhosis.  Invest Radiol. 2002;  37 292-298
    CrossrefPubMedGoogle Scholar
  • 31 Lucidarme O, Baleston F, Cadi M, Bellin M F, Charlotte F, Ratziu V, Grenier P A. Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique?.  Eur Radiol. 2003;  13 467-474
    PubMedGoogle Scholar
  • 32 Weissleder R, Elizondo G, Josephson L, Compton C C, Fretz C J, Stark D D, Ferrucci J T. Experimental lymph node metastases: enhanced detection with MR lymphography.  Radiology. 1989;  171 835-839
    PubMedGoogle Scholar
  • 33 Hamm B, Taupitz M, Hussmann P, Wagner S, Wolf K J. MR lymphography with iron oxide particles: dose-response studies and pulse sequence optimization in rabbits.  Am J Roentgenol. 1992;  158 183-190
    PubMedGoogle Scholar
  • 34 Taupitz M, Wagner S, Hamm B, Binder A, Pfefferer D. Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits.  Am J Roentgenol. 1993;  161 193-200
    PubMedGoogle Scholar
  • 35 Weissleder R, Elizondo G, Wittenberg J, Lee A S, Josephson L, Brady T J. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging.  Radiology. 1990;  175 494-498
    CrossrefPubMedGoogle Scholar
  • 36 Weissleder R, Elizondo G, Wittenberg J, Rabito C A, Bengele H H, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging.  Radiology. 1990;  175 489-493
    CrossrefPubMedGoogle Scholar
  • 37 Mühler A, Zhang X, Wang H, Lawaczeck R, Weinmann H J. Investigation of mechanisms influencing the accumulation of ultrasmall superparamagnetic iron oxide particles in lymph nodes.  Invest Radiol. 1995;  30 98-103
    PubMedGoogle Scholar
  • 38 Elste V, Wagner S, Taupitz M, Pfefferer D, Kresse M, Hamm B, Berg R, Wolf K J, Semmler W. Magnetic resonance lymphography in rats: effects of muscular activity and hyperthermia on the lymph node uptake of intravenously injected superparamagnetic iron oxide particles.  Acad Radiol. 1996;  3 660-666
    PubMedGoogle Scholar
  • 39 Clement O, Rety F, Cuenod C A, Siauve N, Carnot F, Bordat C, Siche M, Frija G. MR lymphography: evidence of extravasation of superparamagnetic nanoparticles into the lymph. Discussion S 183 - S 184.  Acad Radiol. 1998;  5 (Suppl 1) S170-S 172
    PubMedGoogle Scholar
  • 40 Rety F, Clement O, Siauve N, Cuenod C A, Carnot F, Sich M, Buisine A, Frija G. MR lymphography using iron oxide nanoparticles in rats: pharmacokinetics in the lymphatic system after intravenous injection.  J Magn Reson Imaging. 2000;  12 734-739
    CrossrefPubMedGoogle Scholar
  • 41 Wagner S, Pfefferer D, Ebert W, Kresse M, Taupitz M, Hamm B, Lawaczeck R, Wolf K J. Intravenous MR lymphography with superparamagnetic iron oxide particles: Experimental studies in rats and rabbits.  Eur Radiol. 1995;  5 640-646
    PubMedGoogle Scholar
  • 42 Bellin M F, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, Tuchmann C, Richard F, Jacqmin D, Delcourt A, Challier E, Lebret T, Cluzel P. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - initial clinical experience.  Radiology. 1998;  207 799-808
    CrossrefPubMedGoogle Scholar
  • 43 Harisinghani M G, Saini S, Weissleder R, Hahn P F, Yantiss R K, Tempany C, Wood B J, Mueller P R. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation.  Am J Roentgenol. 1999;  172 1347-1351
    PubMedGoogle Scholar
  • 44 Hoffman H T, Quets J, Toshiaki T, Funk G F, McCulloch T M, Graham S M, Robinson R A, Schuster M E, Yuh W T. Functional magnetic resonance imaging using iron oxide particles in characterizing head and neck adenopathy.  Laryngoscope. 2000;  110 1425-1430
    PubMedGoogle Scholar
  • 45 Hudgins P A, Anzai Y, Morris M R, Lucas M A. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study.  Am J Neuroradiol. 2002;  23 649-656
    PubMedGoogle Scholar
  • 46 Mack M G, Balzer J O, Straub R, Eichler K, Vogl T J. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes.  Radiology. 2002;  222 239-244
    CrossrefPubMedGoogle Scholar
  • 47 Harisinghani M G, Saini S, Slater G J, Schnall M D, Rifkin M D. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations.  J Magn Reson Imaging. 1997;  7 161-163
    CrossrefPubMedGoogle Scholar
  • 48 Pannu H K, Wang K P, Borman T L, Bluemke D A. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent.  J Magn Reson Imaging. 2000;  12 899-904
    CrossrefPubMedGoogle Scholar
  • 49 Sigal R, Vogl T, Casselman J, Moulin G, Veillon F, Hermans R, Dubrulle F, Viala J, Bosq J, Mack M, Depondt M, Mattelaer C, Petit P, Champsaur P, Riehm S, Dadashitazehozi Y, de Jaegere T, Marchal G, Chevalier D, Lemaitre L, Kubiak C, Helmberger R, Halimi P. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) - results of a phase-III multicenter clinical trial.  Eur Radiol. 2002;  12 1104-1113
    CrossrefPubMedGoogle Scholar
  • 50 Seneterre E, Weissleder R, Jaramillo D, Reimer P, Lee A S, Brady T J, Wittenberg J. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging.  Radiology. 1991;  179 529-533
    PubMedGoogle Scholar
  • 51 Daldrup-Link H E, Rummeny E J, Ihssen B, Kienast J, Link T M. Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow.  Eur Radiol. 2002;  12 1557-1566
    CrossrefPubMedGoogle Scholar
  • 52 Daldrup H E, Link T M, Blasius S, Strozyk A, Konemann S, Jurgens H, Rummeny E J. Monitoring radiation-induced changes in bone marrow histopathology with ultra-small superparamagnetic iron oxide (USPIO)-enhanced MRI.  J Magn Reson Imaging. 1999;  9 643-652
    CrossrefPubMedGoogle Scholar
  • 53 Daldrup-Link H E, Reinlander C, Link T M, Richter K J, Konemann S, Rummeny E J. Experimentelle Untersuchungen zur Wertigkeit von SPIO für die MRT des Knochenmarks vor und nach Ganzkörperbestrahlung.  Fortschr Röntgenstr. 2001;  173 547-553
    PubMedGoogle Scholar
  • 54 Fleige G, Nolte C, Synowitz M, Seeberger F, Kettenmann H, Zimmer C. Magnetic labeling of activated microglia in experimental gliomas.  Neoplasia. 2001;  3 489-499
    CrossrefPubMedGoogle Scholar
  • 55 Beckmann N, Joergensen J, Bruttel K, Rudin M, Schuurman H J. Magnetic resonance imaging for the evaluation of rejection of a kidney allograft in the rat.  Transplant International. 1996;  9 175-183
    CrossrefPubMedGoogle Scholar
  • 56 Kanno S, Lee P C, Dodd S J, Williams M, Griffith B P, Ho C. A novel approach with magnetic resonance imaging used for the detection of lung allograft rejection.  J Thorac Cardiovasc Surg. 2000;  120 923-934
    CrossrefPubMedGoogle Scholar
  • 57 Kanno S, Wu Y J, Lee P C, Dodd S J, Williams M, Griffith B P, Ho C. Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles.  Circulation. 2001;  104 934-938
    CrossrefPubMedGoogle Scholar
  • 58 Mühler A, Freise C E, Kuwatsuru R, Rosenau W, Liu T, Mintorovitch J, Clement O, Vexler V, Mahboubi S, Lang P. Acute liver rejection: evaluation with cell-directed MR contrast agents in a rat transplantation model.  Radiology. 1993;  186 139-146
    PubMedGoogle Scholar
  • 59 Allkemper T, Bremer C, Matuszewski L, Ebert W, Reimer P. Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits.  Radiology. 2002;  223 432-438
    CrossrefPubMedGoogle Scholar
  • 60 Urhahn R, Adam G, Busch N, Chen J H, Euringer W, Gunther R A. Superparamagnetische Eisenoxidpartikel: Welchen Stellenwert hat der T1-Effekt für die MR-Diagnostik fokaler Leberläsionen?.  Fortschr Röntgenstr. 1996;  165 364-370
    PubMedGoogle Scholar
  • 61 Knollmann F D, Böck J C, Teltenkotter S, Wlodarczyk W, Mühler A, Vogl T J, Felix R. Evaluation of portal MR angiography using superparamagnetic iron oxide.  J Magn Reson Imaging. 1997;  7 191-196
    CrossrefPubMedGoogle Scholar
  • 62 Reimer P, Marx C, Rummeny E J, Muller M, Lentschig M, Balzer T, Dietl K H, Sulkowski U, Berns T, Shamsi K, Peters P E. SPIO-enhanced 2D-TOF MR angiography of the portal venous system: results of an intraindividual comparison.  J Magn Reson Imaging. 1997;  7 945-949
    PubMedGoogle Scholar
  • 63 Schmitz S A, Albrecht T, Jensen K, Wolf K J. SPIO-unterstützte MR- Angiographie des portalvenösen Systems.  Fortschr Röntgenstr. 2000;  172 51-54
    PubMedGoogle Scholar
  • 64 Schmitz S A, Albrecht T, Wolf K J. MR angiography with superparamagnetic iron oxide: feasibility study.  Radiology. 1999;  213 603-607
    CrossrefPubMedGoogle Scholar
  • 65 Clarke S E, Weinmann H J, Dai E, Lucas A R, Rutt B K. Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits.  Radiology. 2000;  214 787-794
    PubMedGoogle Scholar
  • 66 Kellar K E, Fujii D K, Gunther W H, Briley-Saebo K, Spiller M, Koenig S H. „NC100150”, a preparation of iron oxide nanoparticles ideal for positive-contrast MR angiography.  MAGMA. 1999;  8 207-213
    PubMedGoogle Scholar
  • 67 Stillman A E, Wilke N, Li D, Haacke M, McLachlan S. Ultrasmall superparamagnetic iron oxide to enhance MRA of the renal and coronary arteries: studies in human patients.  J Comput Assist Tomogr. 1996;  20 51-55
    CrossrefPubMedGoogle Scholar
  • 68 Hofman M B, Henson R E, Kovacs S J, Fischer S E, Lauffer R B, Adzamli K, De Becker J, Wickline S A, Lorenz C H. Blood pool agent strongly improves 3D magnetic resonance coronary angiography using an inversion pre-pulse.  Magn Reson Med. 1999;  41 360-367
    CrossrefPubMedGoogle Scholar
  • 69 Johansson L O, Nolan M M, Taniuchi M, Fischer S E, Wickline S A, Lorenz C H. High-resolution magnetic resonance coronary angiography of the entire heart using a new blood-pool agent, NC100150 injection: comparison with invasive x-ray angiography in pigs.  J Cardiovasc Magn Reson. 1999;  1 139-143
    PubMedGoogle Scholar
  • 70 Taupitz M, Schnorr J, Wagner S, Abramjuk C, Pilgrimm H, Kivelitz D, Schink T, Hansel J, Laub G, Hunigen H, Hamm B. Coronary MR angiography: experimental results with a monomer-stabilized blood pool contrast medium.  Radiology. 2002;  222 120-126
    CrossrefPubMedGoogle Scholar
  • 71 Sandstede J J, Pabst T, Wacker C, Wiesmann F, Hoffmann V, Beer M, Kenn W, Bauer W, Hahn D. Breath-hold 3D MR coronary angiography with a new intravascular contrast agent (feruglose) - first clinical experiences.  Magn Reson Imaging. 2001;  19 201-205
    PubMedGoogle Scholar
  • 72 Bedaux W L, Hofman W B, Wielopolski P A, de Cock C C, Hoffmann V, Oudkerk M, de Feyter P J, van Rossum A C. Three-dimensional magnetic resonance coronary angiography using a new blood pool contrast agent: initial experience.  J Cardiovasc Magn Reson. 2002;  4 273-282
    CrossrefPubMedGoogle Scholar
  • 73 Knuesel P R, Nanz D, Wolfensberger U, Saranathan M, Lehning A, Luescher T F, Marincek B, Von Schulthess G K, Schwitter J. Multislice breath-hold spiral magnetic resonance coronary angiography in patients with coronary artery disease: Effect of intravascular contrast medium.  J Magn Reson Imaging. 2002;  16 660-667
    CrossrefPubMedGoogle Scholar
  • 74 Amano Y, Herfkens R J, Shifrin R Y, Alley M T, Pelc N J. Three-dimensional cardiac cine magnetic resonance imaging with an ultrasmall superparamagnetic iron oxide blood pool agent (NC100150).  J Magn Reson Imaging. 2000;  11 81-86
    CrossrefPubMedGoogle Scholar
  • 75 Schmitz S A, Coupland S E, Gust R, Winterhalter S, Wagner S, Kresse M, Semmler W, Wolf K J. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits.  Invest Radiol. 2000;  35 460-471
    CrossrefPubMedGoogle Scholar
  • 76 Ruehm S G, Corot C, Vogt P, Kolb S, Debatin J F. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits.  Circulation. 2001;  103 415-422
    CrossrefPubMedGoogle Scholar
  • 77 Schmitz S A, Taupitz M, Wagner S, Wolf K J, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles.  J Magn Reson Imaging. 2001;  14 355-361
    CrossrefPubMedGoogle Scholar
  • 78 Schmitz S A, Winterhalter S, Schiffler S, Gust R, Wagner S, Kresse M, Coupland S E, Semmler W, Wolf K J. USPIO-enhanced direct MR imaging of thrombus: preclinical evaluation in rabbits.  Radiology. 2001;  221 237-243
    CrossrefPubMedGoogle Scholar
  • 79 Johansson L O, Bjornerud A, Ahlstrom H K, Ladd D L, Fujii D K. A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution.  J Magn Reson Imaging. 2001;  13 615-618
    CrossrefPubMedGoogle Scholar
  • 80 Wacker F K, Reither K, Ebert W, Wendt M, Lewin J S, Wolf K J. MR Image-guided Endovascular Procedures with the Ultrasmall Superparamagnetic Iron Oxide SH U 555 C as an Intravascular Contrast Agent: Study in Pigs.  Radiology. 2003;  226 459-464
    PubMedGoogle Scholar
  • 81 Weishaupt D, Hilfiker P R, Schmidt M, Debatin J F. Pulmonary hemorrhage: imaging with a new magnetic resonance blood pool agent in conjunction with breathhold three-dimensional magnetic resonance angiography.  Cardiovasc Intervent Radiol. 1999;  22 321-325
    CrossrefPubMedGoogle Scholar
  • 82 Turetschek K, Huber S, Floyd E, Helbich T, Roberts T P, Shames D M, Tarlo K S, Wendland M F, Brasch R C. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.  Radiology. 2001;  218 562-569
    PubMedGoogle Scholar
  • 83 Turetschek K, Huber S, Helbich T, Floyd E, Tarlo K S, Roberts T PL, Shames D M, Wendland M F, Brasch R C. Dynamic MRI enhanced with albumin-(Gd-DTPA)30 or ultrasmall superparamagnetic iron oxide particles (NC100150 injection) for the measurement of microvessel permeability in experimental breast tumors.  Acad Radiol. 2002;  9 (Suppl 1) S 112-S 114
    PubMedGoogle Scholar
  • 84 Turetschek K, Roberts T P, Floyd E, Preda A, Novikov V, Shames D M, Carter W O, Brasch R C. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model.  J Magn Reson Imaging. 2001;  13 882-888
    CrossrefPubMedGoogle Scholar
  • 85 Daldrup-Link H E, Brasch R C. Macromolecular contrast agents for MR mammography: current status.  Eur Radiol. 2003;  13 354-365
    PubMedGoogle Scholar
  • 86 Ichikawa T, Arbab A S, Araki T, Touyama K, Haradome H, Hachiya J, Yamaguchi M, Kumagai H, Aoki S. Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinoma.  Am J Roentgenol. 1999;  173 207-213
    PubMedGoogle Scholar
  • 87 Rozenman Y, Zou X M, Kantor H L. Magnetic resonance imaging with superparamagnetic iron oxide particles for the detection of myocardial reperfusion.  Magn Reson Imaging. 1991;  9 933-939
    PubMedGoogle Scholar
  • 88 Bjerner T, Johansson L, Ericsson A, Wirkstrom G, Hemmingsson A, Ahlstrom H. First-pass myocardial perfusion MR imaging with outer-volume suppression and the intravascular contrast agent NC100150 injection: preliminary results in eight patients.  Radiology. 2001;  221 822-826
    PubMedGoogle Scholar
  • 89 Panting J R, Taylor A M, Gatehouse P D, Keegan J, Yang G Z, McGill S, Francis J M, Burman E D, Firmin D N, Pennell D J. First-pass myocardial perfusion imaging and equilibrium signal changes using the intravascular contrast agent NC100150 injection.  J Magn Reson Imaging. 1999;  10 404-410
    CrossrefPubMedGoogle Scholar
  • 90 Bjerner T, Ericsson A, Wikstrom G, Johansson L, Nilsson S, Ahlstrom H, Hemmingsson A. Evaluation of nonperfused myocardial ischemia with MRI and an intravascular USPIO contrast agent in an ex vivo pig model.  J Magn Reson Imaging. 2000;  12 866-872
    CrossrefPubMedGoogle Scholar
  • 91 Weissleder R, Reimer P, Lee A S, Wittenberg J, Brady T J. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors.  Am J Roentgenol. 1990;  155 1161-1167
    PubMedGoogle Scholar
  • 92 Schaffer B K, Linker C, Papisov M, Tsai E, Nossiff N, Shibata T, Bogdanov A, Brady T J, Weissleder R. MION-ASF: biokinetics of an MR receptor agent.  Magn Reson Imaging. 1993;  11 411-417
    PubMedGoogle Scholar
  • 93 Reimer P, Weissleder R, Lee A S, Wittenberg J, Brady T J. Receptor imaging: application to MR imaging of liver cancer.  Radiology. 1990;  177 729-734
    PubMedGoogle Scholar
  • 94 Reimer P, Weissleder R, Brady T J, Yeager A E, Baldwin B H, Tennant B C, Wittenberg J. Experimental hepatocellular carcinoma: MR receptor imaging.  Radiology. 1991;  180 641-645
    PubMedGoogle Scholar
  • 95 Leveille-Webster C R, Rogers J, Arias I M. Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats.  Hepatology. 1996;  23 1631-1641
    PubMedGoogle Scholar
  • 96 Reimer P, Weissleder R, Shen T, Knoefel W T, Brady T J. Pancreatic receptors. Initial feasibility studies with a targeted contrast agent for MR imaging.  Radiology. 1994;  193 527-531
    PubMedGoogle Scholar
  • 97 Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways.  Magn Reson Med. 1998;  40 236-242
    CrossrefPubMedGoogle Scholar
  • 98 Schellenberger E A, Bogdanov A, Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: an nanoparticle for detecting apoptosis by MRI.  Molecular Imaging. 2002;  1 102-107
    CrossrefPubMedGoogle Scholar
  • 99 Zhang Y, Kohler N, Zhang M. Intracellular uptake of poyl(ethylene glycol) and folic acid modified magnetite nanoparticles.  Mat Res Soc Symp Proceedings. 2002;  676 Y 981-Y 985
    PubMedGoogle Scholar
  • 100 Cerdan S, Lotscher H R, Kunnecke B, Seelig J. Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors.  Magn Reson Med. 1989;  12 151-163
    PubMedGoogle Scholar
  • 101 Remsen L G, McCormick C I, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, Hellstrom I, Kroll R A, Neuweit E A. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis.  Am J Neuroradiol. 1996;  17 411-418
    PubMedGoogle Scholar
  • 102 Weissleder R, Lee A S, Fischman A J, Reimer P, Shen T, Wilkinson R, Callahan R J, Brady T J. Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging.  Radiology. 191;  181 245-249
    PubMedGoogle Scholar
  • 103 Weissleder R, Lee A S, Khaw B A, Shen T, Brady T J. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging.  Radiology. 1992;  182 381-385
    PubMedGoogle Scholar
  • 104 Kang H W, Josephson L, Petrovsky A, Weissleder R, Bogdanov A. Magnetic Resonance Imaging of Inducible E-Selectin Expression in Human Endothelial Cell Culture.  Bioconjugate Chemistry. 2002;  13 122-127
    CrossrefPubMedGoogle Scholar
  • 105 Tiefenauer L X, Kuehne G, Andres R Y. Antibody-magnetite nanoparticles: In vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging.  Bioconjugate Chemistry. 1993;  4 347-352
    CrossrefPubMedGoogle Scholar
  • 106 Suzuki M, Honda H, Kobayashi T, Wakabayashi T, Yoshida J, Takahashi M. Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles.  Noshuyo Byori. 1996;  13 127-132
    PubMedGoogle Scholar
  • 107 Suwa T, Ozawa S, Ueda M, Ando N, Kitajima M. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody.  Int J Cancer. 1998;  75 626-634
    CrossrefPubMedGoogle Scholar
  • 108 Schulze E, Ferrucci J T, Poss K, Lapointe L, Bogdanova A, Weissleder R. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro.  Invest Radiol. 1995;  30 604-610
    PubMedGoogle Scholar
  • 109 Weissleder R, Cheng H C, Bogdanova A, Bogdanova A J. Magnetically labeled cells can be detected by MR imaging.  J Magn Reson Imaging. 1997;  7 258-263
    CrossrefPubMedGoogle Scholar
  • 110 Fleige G, Seeberger F, Laux D, Kresse M, Taupitz M, Pilgrimm H, Zimmer C. In Vitro Characterization of Two Different Ultrasmall Iron Oxide Particles for Magnetic Resonance Cell Tracking.  Invest Radiol. 2002;  37 482-488
    CrossrefPubMedGoogle Scholar
  • 111 Franklin R J, Blaschuk K L, Bearchell M C, Prestoz L L, Setzu A, Brindle K M. FrenchConstant C: Magnetic resonance imaging of transplanted oligodendrocyte precursors in the rat brain.  Neuroreport. 1999;  10 3961-3965
    PubMedGoogle Scholar
  • 112 Lewin M, Carlesso N, Tung C H, Tang X W, Cory D, Scadden D T, Weissleder R. Tat peptide derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells.  Nature Biotechnology. 2000;  18 410-414
    CrossrefPubMedGoogle Scholar
  • 113 Bulte J WM, Douglas T, Witwer B, Zhang S-C, Strable E, Lewis B K, Zywicke H, Miller B, van Gelderen P, Moskowitz B M, Duncan L D, Frank J A. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells.  Nature Biotechnology. 2001;  19 1141-1147
    CrossrefPubMedGoogle Scholar
  • 114 Bulte J WM, Duncan I D, Frank J A. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation.  J Cerebr Blood Flow Metabol. 2002;  22 899-907
    PubMedGoogle Scholar
  • 115 Chan T W, Eley C, Liberti P, So A, Kressel H Y. Magnetic resonance imaging of abscesses using lipid-coated iron oxide particles.  Invest Radiol. 1992;  27 443-449
    CrossrefPubMedGoogle Scholar
  • 116 Yeh T C, Zhang W, Ilstad S T, Ho C. Intracellular labeling of T-cells with superparamagnetic contrast agents.  Magn Reson Med. 1993;  30 617-625
    PubMedGoogle Scholar
  • 117 Krieg F M, Andres R Y, Winterhalter K H. Superparamagnetically labelled neutrophils as potential abscess-specific contrast agent for MRI.  Magn Reson Imaging. 1995;  13 393-400
    PubMedGoogle Scholar
  • 118 Yeh T C, Zhang W, Ildstad S T, Ho C. In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles.  Magn Reson Med. 1995;  33 200-208
    PubMedGoogle Scholar
  • 119 Lonnemark M, Hemmingsson A, Bach-Gansmo T, Ericsson A, Oksendal A, Nyman R, Moxnes A. Effect of superparamagnetic particles as oral contrast medium at magnetic resonance imaging. A phase I clinical study.  Acta Radiologica. 1989;  30 193-196
    PubMedGoogle Scholar
  • 120 Briggs R W, Wu Z, Mladinich C RJ, Stoupis C, Gauger J, Liebig T, Ros P R, Ballinger J R, Kubilis P. In vivo animal tests of an artifact-free contrast agent for gastrointestinal MRI.  Magn Reson Imaging. 1997;  15 559-566
    PubMedGoogle Scholar
  • 121 D'Arienzo A, Scaglione G, Vicinanza G, Manguso F, Bennato R, Belfiore G, Imbriaco M, Mazzacca G. Magnetic resonance imaging with ferumoxil, a negative superparamagnetic oral contrast agent, in the evaluation of ulcerative colitis.  Am J Gastroenterol. 2000;  95 720-724
    CrossrefPubMedGoogle Scholar
  • 122 Pauser S, Reszka R, Wagner S, Wolf K J, Buhr H J, Berger G. Liposome-encapsulated superparamagnetic iron oxide particles as markers in an MRI-guided search for tumor-specific drug carriers.  Anti-Cancer Drug Design. 1997;  12 125-135
    PubMedGoogle Scholar
  • 123 Kim D K, Zhang Y, Voit W, Rao K V, Kehr J, Bjelke B, Muhammed M. Superparamagnetic iron oxide nanoparticles for bio-medical applications.  Scripta Materialia. 2001;  44 1713-1717
    CrossrefPubMedGoogle Scholar
  • 124 Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca E A, Basilion J P. In vivo magnetic resonance imaging of transgene expression.  Nature Medicine. 2000;  6 351-354
    CrossrefPubMedGoogle Scholar
  • 125 Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, Gansbacher B, Plank C. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo.  Gene Therapy. 2002;  9 102-109
    CrossrefPubMedGoogle Scholar
  • 126 von Ardenne M, Kirsch R. (On the methodology of extreme hyperthermia, with special reference to multi-step cancer chemotherapy).  Dtsch Gesundheitsw. 1965;  20 1935-1940 contd
    PubMedGoogle Scholar
  • 127 Sako M, Hirota S. Embolotherapy of hepatomas using ferromagnetic microspheres, its clinical evaluation and the prospect of its use as a vehicle in chemoembolo-hyperthermic therapy.  Gan to Kagaku Ryoho (Japanese J Cancer Chemother). 1986;  13 1618-1624
    PubMedGoogle Scholar
  • 128 Moroz P, Jones S K, Winter J, Gray B N. Targeting liver tumors with hyperthermia: Ferromagnetic embolization in a rabbit liver tumor model.  J Surg Oncol. 2001;  78 22-29
    CrossrefPubMedGoogle Scholar
  • 129 Moroz P, Jones S K, Gray B N. Tumor response to arterial embolization hyperthermia and direct injection hyperthermia in a rabbit liver tumor model.  J Surg Oncol. 2002;  80 149-156
    CrossrefPubMedGoogle Scholar
  • 130 Jung C W, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.  Magn Reson Imaging. 1995;  13 661-674
    PubMedGoogle Scholar
  • 131 Tanimoto A, Yuasa Y, Hiramatsu K. Enhancement of phase-contrast MR angiography with superparamagnetic iron oxide.  J Magn Reson Imaging. 1998;  8 446-450
    CrossrefPubMedGoogle Scholar
  • 132 Wagner S, Schnorr J, Pilgrim H, Hamm B, Taupitz M. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: Preclinical in vivo characterization.  Invest Radiol. 2002;  37 167-177
    CrossrefPubMedGoogle Scholar

Dr. med. Matthias Taupitz

Institut für Radiologie, Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin

Schumannstraße 20/21

10098 Berlin

Phone: + 49-30-450527032

Fax: + 49-30-450527922

Email: matthias.taupitz@charite.de

      >